Exchange: NASDAQ·Updated 03:16 AM EDT
News
all
press releases
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced
A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.
Stocktwits
More News
How S&P 500, Nasdaq, Dow Futures Are Moving As Trump’s ‘Economic D-Day’ On Iran, Nvidia Earnings Loom
U.S. Treasury Secretary Scott Bessent said in a post on X that ‘an economic D-Day’ was about to dawn on Iran on Monday, when Washington is expected to announce fresh sanctions against the Middle Eastern country.
Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation
The stock has gained over 20% in the past five days, marking its best week since early July.
Stocktwits
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Stocktwits
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Stocktwits
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment
Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.
Stocktwits
Why Are Nasdaq, S&P 500 Futures Tumbling Premarket? META, TSLA, NVDA, MU, NBIS, SLS, HD Stocks In Focus
Retail sentiment on Stocktwits remained ‘bullish’ on SPY and moderated to ‘neutral’ on QQQ.
Stocktwits
SLS Stock Extends Rally To 4 Days: Jefferies Discloses New Stake, CEO Signals AML Database-Lock Preparations
A separate pediatric study delivered “striking” WT1 vaccine results, supporting GPS’s scientific rationale, the company's CEO said.
Stocktwits
Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial
Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.
Stocktwits
Why Are Nasdaq, S&P 500 Futures Rising Premarket? SPCX, NVDA, SNDK, MU, NLST, BABA, SLS, RKLB Stocks In Focus
Retail sentiment on Stocktwits remained ‘bullish’ on SPY and moderated to ‘neutral’ on QQQ.
Stocktwits

Advertisement|Remove ads.